In fact, Kaplan–Meier survival analysis showed that when mice with FGFR3 mutant bladder cancer are treated with combination therapy, they have a much higher probability of surviving to day 25 compared to mice treated with either monotherapy. Here, FGFR3 is linked to urinary bladder cancer.